| IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights |
Primary endpoint of pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine in patients with advanced melanoma still expected to readout in third quarter of 2025 Data presented at recent congresses reinforces the potential of the company's T-Win candidates to reshape the tumor microenvironment and drive more effective anti-tumor responses Company recognized as one of the most innovative biotechnology companies in the world by Fast Company Company to participate in TD Cowen's 6th Annual Oncology Innovation Summit on May 27 and Jefferies Global Healthcare Conference on June 4, 2025 NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today reported financial results and business highlights for the first quarter of 2025. The company continues to advance its pipeline, presenting new data further defining the mechanism of action for its T-Win therapeutic cancer vaccines, and reaffirming its expectation that the Phase 3 pivotal trial will readout in the third quarter of 2025. |
globenewswire.com |
2025-05-14 12:05:00 |
Czytaj oryginał (ang.) |
| IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025 |
NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that one of its scientific co-founders, Mads Hald Andersen, DMSc, PhD, Director of the National Center for Cancer Immune Therapy (CCIT-DK), chaired and presented at an educational session on cancer vaccines at the 2025 American Association for Cancer Research (AACR) Annual Meeting. The session brought together leading oncology scientists and explored the latest advancements in cancer vaccine research, from preclinical innovation to clinical implementation, providing perspective on the future of cancer vaccines and their potential to reshape cancer immunotherapy (session #ED59). |
globenewswire.com |
2025-04-26 19:05:00 |
Czytaj oryginał (ang.) |
| IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170 |
Preclinical data further support the potential of dual-antigen and TGF-β-directed vaccines to reshape the tumor microenvironment and drive anti-tumor immunity NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced the presentation of new preclinical data for two vaccine candidates developed based on its T-win® platform at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, Illinois. One poster presentation provides further insights on the mode of action of IO102-IO103, the company's lead investigational therapeutic cancer vaccine which targets cells expressing IDO1 and PD-L1, compared to conventional checkpoint inhibitors and a second shares promising updates for IO170, which targets Transforming Growth Factor beta (TGF-β). |
globenewswire.com |
2025-04-25 17:00:00 |
Czytaj oryginał (ang.) |
| IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting |
• New non-clinical data strengthens evidence of contributions of IO102 and IO103 to tumor growth control through target specific T-cell activation, offering a distinct and complementary approach to checkpoint inhibitors • New preclinical data for IO170 add to growing body of evidence supporting the potential of immune-modulatory therapeutic cancer vaccines to treat a wide range of cancers NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that two abstracts have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025 taking place April 25-30 in Chicago, Illinois. One of the posters will share insights, using non-clinical models, related to IO Biotech's lead investigational candidate, IO102-IO103, currently being evaluated in a pivotal Phase 3 trial in advanced melanoma. |
globenewswire.com |
2025-03-25 18:35:00 |
Czytaj oryginał (ang.) |
| IO Biotech Named Among Fast Company's World's Most Innovative Companies of 2025 |
– Biopharmaceutical company recognized for innovation in the development of immune-modulatory therapeutic cancer vaccines – NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company, has been named to Fast Company's prestigious list of the World's Most Innovative Companies of 2025. Fast Company recognizes 609 organizations across 58 sectors and regions. |
globenewswire.com |
2025-03-18 10:00:00 |
Czytaj oryginał (ang.) |
| IO Biotech Reports 2024 Business Highlights |
Preparations for submission of a Biologics License Application (BLA) for Cylembi o ® (imsapepimut and etimupepimut, adjuvanted) to FDA by year end 2025 remain on track. The trial completed enrollment in December 2023 ahead of plan with 407 patients. |
globenewswire.com |
2025-03-04 18:17:00 |
Czytaj oryginał (ang.) |
| IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference |
• Findings support the development of a novel peptide vaccine targeting the immunosuppressive effects of Transforming Growth Beta (TGF- β ) in solid tumors NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced details of its poster presentation at the American Association for Cancer Research (AACR)-IO conference taking place February 23-26, 2025, in Los Angeles, California. Poster Presentation Details Title: A TGF-β-directed peptide vaccine induces T cell activation & drives anti-tumor activity by modulating the architecture of the tumor microenvironment Poster number: B117 Presenter: Matteo Bocci, PhD, Senior Scientist Date and time: Tuesday, February 25, 2025, 1:45-4:00 PM PST Location: JW Marriott Los Angeles, Platinum Ballroom A-E Transforming Growth Factor Beta (TGF-β) is a key immune-suppressive factor in the tumor microenvironment (TME) of most solid tumors, often limiting the efficacy of various immune-oncology therapies. |
globenewswire.com |
2025-02-23 14:07:00 |
Czytaj oryginał (ang.) |
| IO Biotech to Present at the 45th Annual Cowen Health Care Conference |
Presentation will include an update on the development and launch preparations of Cylembio™ (imsapepimut and etimupepimut, adjuvanted) NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that Mai-Britt Zocca, PhD, President and CEO, will present a company overview at the 45th Annual Cowen Health Care Conference to be held March 3-5, 2025 in Boston, MA. Dr. Zocca, joined by Amy Sullivan, CFO, and Qasim Ahmad, MD, CMO, will also be hosting one-on-one investor meetings during the conference. |
globenewswire.com |
2025-02-20 10:05:00 |
Czytaj oryginał (ang.) |
| IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate |
– Submission of Investigational New Drug Application (IND) to US FDA expected in 2025 – NEW YORK, Feb. 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced the publication of results from a preclinical study of its second immune-modulatory therapeutic cancer vaccine candidate, IO112, targeting arginase 1 (Arg1), in the Journal for ImmunoTherapy of Cancer. These preclinical data further expand upon previously reported data that IO112 treatment inhibits tumor growth through dynamic changes in the tumor microenvironment (TME). |
globenewswire.com |
2025-02-04 10:05:00 |
Czytaj oryginał (ang.) |
| IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer |
-- Enrollment Completed Ahead of Schedule -- -- Initial Data Expected in 2025 -- |
globenewswire.com |
2025-01-09 10:05:00 |
Czytaj oryginał (ang.) |
| IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank |
COPENHAGEN, Denmark and NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating, off-the-shelf therapeutic cancer vaccines today announced that it has entered into a loan facility of up to €57.5 million from the European Investment Bank (EIB), the long-term lending institution of the European Union owned by its Member States. The debt facility includes three committed tranches totaling up to €37.5 million, which will become available if the company satisfies certain conditions, and one uncommitted accordion tranche of €20 million. The company expects the first two tranches to be available for disbursement in the first quarter of 2025. |
globenewswire.com |
2024-12-20 10:05:00 |
Czytaj oryginał (ang.) |
| IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights |
Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced melanoma on track with primary endpoint of progression free survival (PFS) projected to be reached in first half of 2025 Primary endpoint met in Phase 2 basket trial (IOB-022/KN-D38) cohort evaluating IO102-IO103 in combination with pembrolizumab in the first-line treatment of advanced squamous cell carcinoma of the head and neck (SCCHN) Enrollment in Phase 2 basket trial (IOB-032/PN-E40) evaluating IO102-IO103 in combination with pembrolizumab as neoadjuvant and adjuvant treatment of patients with resectable melanoma or SCCHN is proceeding ahead of schedule Ended third quarter with approximately $80 million in cash and cash equivalents; the company continues to expect its cash position will support operations into the fourth quarter of 2025 NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today reported financial results for the third quarter ended September 30, 2024. “We continue to add to the body of evidence that our novel investigational therapeutic cancer vaccine, IO102-IO103, has the potential to bring clinical benefit to patients with strong signals of activity now observed in patients with three types of metastatic solid tumors,” said Mai-Britt Zocca, PhD, President and CEO of IO Biotech. |
globenewswire.com |
2024-11-12 09:05:00 |
Czytaj oryginał (ang.) |
| IO Biotech Announces Participation in Upcoming Investor Conferences |
NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that members of its senior management team will participate in the following upcoming investor conferences: Event: Jefferies London Healthcare ConferenceLocation: LondonOne-on-one meetings: Wednesday, November 20, 2024Participants: Mai-Britt Zocca, PhD, President and CEO and Amy Sullivan, CFO Event: Piper Sandler 36th Annual Healthcare ConferenceLocation: New York, New YorkFireside chat: Tuesday, December 3, 2024 at 11:00 am ETPresenter: Mai-Britt Zocca, PhD, President & CEOWebcast Link: https://event.webcasts.com/starthere.jsp?ei=1697959&tp_key=934ba9e309 A webcast replay of the Piper Sandler fireside chat will be available on IO Biotech's website at www.iobiotech.com for 90 days following the presentation. About IO102-IO103 IO102-IO103 is an investigational off-the-shelf therapeutic cancer vaccine designed to kill both tumor cells and immune-suppressive cells in the tumor microenvironment (TME) by stimulating activation and expansion of T cells against indoleamine 2,3-dioxygenase (IDO) positive and/or programmed death-ligand 1 (PD-L1) positive cells. |
globenewswire.com |
2024-11-11 18:05:00 |
Czytaj oryginał (ang.) |
| IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study |
-- Metastatic non-small cell lung cancer (NSCLC) patients treated in the first line setting with IO102-IO103 in combination with Keytruda ® demonstrated promising activity with an overall response rate of 55% unconfirmed/48% confirmed, disease control rate of 81%, and approximately 50% of patients without disease progression at 12 months; median duration of response not reached -- -- Safety profile consistent with prior studies with the combination, showing no unexpected toxicities compared to anti-PD1 monotherapy, and low-grade transient injection site reactions as the most common treatment related adverse event -- |
globenewswire.com |
2024-11-07 12:00:00 |
Czytaj oryginał (ang.) |
| IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting |
NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced two abstracts accepted for poster presentation at the Society for Immunotherapy of Cancer's 39th Annual Meeting (SITC 2024) taking place taking place in Houston, Texas on November 8-10, 2024. |
globenewswire.com |
2024-10-04 13:00:00 |
Czytaj oryginał (ang.) |
| IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer |
-- Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the Head and Neck Cohort -- -- No New Safety Signals or Added Systemic Safety Concerns Observed -- |
globenewswire.com |
2024-09-14 06:30:00 |
Czytaj oryginał (ang.) |
| IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma |
- Based on a per-protocol interim analysis of safety and efficacy data, the Independent Data Monitoring Committee (IDMC) recommended that the trial continue without modifications- No new safety signals observed at interim analysis- Primary endpoint of progression free survival projected to be reached in the first half of 2025 |
globenewswire.com |
2024-08-30 20:05:00 |
Czytaj oryginał (ang.) |
| IO Biotech Announces Participation in Upcoming Investor Conferences |
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that members of its senior management team will provide a corporate update and participate in one-on-one meetings at the following upcoming investor conferences: Event: Morgan Stanley 22nd Annual Global Healthcare ConferenceLocation: New York, New YorkFireside Chat Date & Time: Wednesday, September 4, 2024 at 5:35 pm ETPresenter: Mai-Britt Zocca, PhD, CEOWebcast Link: Here Event: H.C. Wainwright 26th Annual Global Investment ConferenceLocation: New York, New YorkPresentation Time: Monday, September 9, 2024 at 10:30 am ETPresenter: Amy Sullivan, CFO Webcast Link: Here A webcast replay of the presentations will be available on IO Biotech's website at www.iobiotech.com for 90 days following the presentation. |
globenewswire.com |
2024-08-26 20:05:00 |
Czytaj oryginał (ang.) |
| IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights |
Phase 3 interim analysis outcome still expected in Q3 2024 for the overall response rate (ORR) in the pivotal trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced melanoma ; outcome of primary endpoint of progression free survival (PFS) expected in first half of 2025 Completed enrollment in Phase 2 basket trial IOB-022/KN-D38 evaluating IO102-IO103 in combination with pembrolizumab in patients with non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN); data from SCCHN cohort has been accepted for poster presentation at the European Society for Medical Oncology (ESMO 2024) congress; abstract with data from NSCLC cohort has been submitted for poster presentation at an upcoming fall medical meeting Completed enrollment in first cohort (cohort A) of Phase 2 solid tumor basket trial (IOB-032/PN-E40) evaluating IO102-IO103 in combination with pembrolizumab as neoadjuvant and adjuvant treatment of patients with resectable solid tumors; initiated enrollment in randomized melanoma cohort Ended second quarter with approximately $100.7 million in cash and cash equivalents; the company confirms that cash position is expected to support operations into the fourth quarter of 2025 NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today reported financial results for the second quarter ended June 30, 2024. “During the first half of this year, we've continued to execute on our mission of developing breakthrough cancer vaccines that could potentially change the treatment paradigm for people living with melanoma and other types of cancer,” said Mai-Britt Zocca, PhD, President and CEO of IO Biotech. |
globenewswire.com |
2024-08-13 11:05:00 |
Czytaj oryginał (ang.) |
| 3 Penny Stocks with 190% Growth Potential According to Wall Street Analysts |
Penny stocks are a fascinating category of investment opportunities. |
247wallst.com |
2024-08-12 19:27:22 |
Czytaj oryginał (ang.) |
| IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024 |
NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, announced today that an abstract related to IO102-IO103, the company's lead investigational therapeutic cancer vaccine candidate, has been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2024. The poster will share data from one of the Phase 2 basket trials of IO102-IO103 in combination with pembrolizumab (KEYTRUDA®), Merck's anti-PD-1 therapy. The data for the complete squamous cell carcinoma of the head and neck (SCCHN) cohort of the IOB-022/KN-D38 study will be presented at the Congress, which takes place in Barcelona from September 13-17, 2024. |
globenewswire.com |
2024-07-25 20:05:00 |
Czytaj oryginał (ang.) |
| 3 Undervalued Biotech Gems With 200%+ Analyst Price Targets |
One of the critical components of the investing world is the proliferation and understanding of analyst predictions. That's because most retail investors prefer to research consumer information regarding stock picks through the calculations of those deemed more experienced in understanding financial fundamentals. |
investorplace.com |
2024-07-04 14:01:38 |
Czytaj oryginał (ang.) |
| IO Biotech to Present at Jefferies Global Healthcare Conference |
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, announced today that Mai-Britt Zocca, Ph.D., the company's President and CEO, will be presenting, and both Dr. Zocca and Amy Sullivan, the company's CFO, will be participating in one-on-one investor meetings at the Jefferies Global Healthcare Conference to be held June 4-6, 2024 in New York, NY. |
globenewswire.com |
2024-05-23 12:30:00 |
Czytaj oryginał (ang.) |
| IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights |
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today reported financial results for the first quarter ended March 31, 2024. |
globenewswire.com |
2024-05-14 11:55:00 |
Czytaj oryginał (ang.) |
| IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting |
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced the acceptance of an abstract related to IO102-IO103, the company's lead investigational therapeutic cancer vaccine candidate, for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago May 31-June 4, 2024. A trial-in-progress poster from the actively recruiting IOB-032/PN-E40 Phase 2 trial (NCT05280314) studying treatment with IO102-IO103 in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) given in the perioperative setting in patients with resectable melanoma or squamous cell carcinoma of the head and neck (SCCHN) will be presented. |
globenewswire.com |
2024-04-24 20:30:00 |
Czytaj oryginał (ang.) |
| IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness |
NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Marjan Shamsaei, PharmD, joined the company as SVP, Commercial Development and Portfolio Lead for IO102-IO103, the company's lead cancer vaccine candidate currently in a pivotal Phase 3 trial. Ms. Shamsaei joins the company's executive team, reporting to IO Biotech CEO Mai-Britt Zocca, Ph.D. |
globenewswire.com |
2024-04-15 12:30:00 |
Czytaj oryginał (ang.) |
| IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103 |
NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today shared new data related to the company's lead therapeutic cancer vaccine candidate, IO102-IO103, at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, California. “These data build on earlier studies that demonstrated the mechanism of IO102 and IO103,” said Mai-Britt Zocca, Ph.D. |
globenewswire.com |
2024-04-09 16:00:00 |
Czytaj oryginał (ang.) |
| IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer |
NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Faiçal Miyara, Ph.D., has been appointed as the company's chief business officer. |
globenewswire.com |
2024-04-05 12:30:00 |
Czytaj oryginał (ang.) |
| IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting |
New nonclinical data strengthen evidence of individual contribution of IO102 and IO103 in controlling tumor growth NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that an abstract has been accepted for presentation at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024), taking place April 5-10, 2024 in San Diego, CA. The poster will include nonclinical data related to IO Biotech's lead therapeutic cancer vaccine candidate, IO102-IO103, currently being evaluated in a pivotal Phase 3 study. |
globenewswire.com |
2024-03-06 18:11:00 |
Czytaj oryginał (ang.) |
| IO Biotech Announces 2023 Fourth-Quarter and Year-End Results |
Completed enrollment of pivotal Phase 3 trial of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with KEYTRUDA® (pembrolizumab), in patients with advanced melanoma; planned interim analysis for overall response rate (ORR) expected in third quarter of 2024 by independent data monitoring committee Progressed clinical development of IO102-IO103 with first patient dosed in Phase 2 basket trial of IO102-IO103 in combination with pembrolizumab as neoadjuvant and adjuvant treatment of patients with resectable solid tumors Ended 2023 with cash and cash equivalents of approximately $143.2 million; expected operational runway into the fourth quarter of 2025 NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today reported financial results for the fourth quarter and year-ended December 31, 2023. “In 2023, we reached a significant milestone in our pivotal Phase 3 trial evaluating our lead therapeutic cancer vaccine, IO102-IO103, in combination with KEYTRUDA, completing enrollment in this trial in mid-November,” said Mai-Britt Zocca, Ph.D. |
globenewswire.com |
2024-03-05 18:40:00 |
Czytaj oryginał (ang.) |